Clinical beta

FMBM is currently in clinical beta. Content is for professional review/testing and must not replace local protocols, senior clinical judgment, or official prescribing references.

Drug Monograph

Nitrous-Oxide

USE IF: Short-term analgesia (ER, labor, minor procedures)

AVOID IF: Any trapped gas condition, B12 deficiency

Nitrous Oxide

Inhalational analgesic/anesthetic gas (NMDA antagonist)

EntonoxProcedural analgesiaLaborPrehospital

Indication

Short-term analgesia (ER, labor, minor procedures)

At a glance

INDICATION -> Rapid-onset inhaled analgesic with minimal sedation but critical gas-expansion risks

ADULT DOSE -> 30-70% N2O with oxygen (minimum 30% O2); commonly 50% N2O / 50% O2 (Entonox), self-administered

MAX DOSE -> Prefer <=6 hours continuous use

CONTRA -> Any trapped-gas condition, severe B12 deficiency

ANTIDOTE -> None (O2 + supportive care; B12 if deficiency)

Quick facts

Onset

30-60 sec

Duration

Peak 3-5 min; effect ends within minutes after stopping due to rapid pulmonary elimination.

Routes

Inhalation ONLY

Pregnancy

Safe for labor analgesia

Renal

No adjustment

Hepatic

No adjustment

Do not miss

Time to action: onset 30-60 sec

Gas expansion risk

  • ABSOLUTE contraindication in pneumothorax and trapped gas states — life-threatening expansion.
  • Trapped gas expansion can be life-threatening (pneumothorax, bowel obstruction, intracranial air).
  • Bowel obstruction → high risk of perforation from gas expansion.
  • Expands air-filled spaces: ETT cuff, bowel, middle ear, intracranial air.

Critical risks

  • B12 inactivation — neurologic injury risk even with short exposure in susceptible patients.
  • Diffusion hypoxia — administer 100% oxygen for at least 5 minutes after discontinuation.
  • Avoid with opioids in labor due to respiratory depression risk.

Antidote

  • No direct antidote; oxygen and supportive care, plus B12 replacement when indicated.

High-risk scenarios

  • Cannot achieve surgical anesthesia alone (MAC >100%) → risk of inadequate anesthesia.
  • Pulmonary hypertension → risk of acute RV decompensation.

Key interactions

  • Opioids.
  • Benzodiazepines.
  • Alcohol/CNS depressants.
  • Underlying B12 deficiency.

Indications

Primary

  • Acute pain (trauma, fractures, burns)
  • Labor analgesia
  • Minor procedures (ER/dental)

Secondary

  • Adjunct in anesthesia (about 30-70%)
  • Bedside procedures

Other

  • ICU inhalational sedation (off-label/specialized)
  • Refractory bronchospasm (off-label)

Dosing

Standard: 50% N2O / 50% O2 inhaled PRN

Max daily dose

  • Must not deliver hypoxic mixtures — ensure adequate FiOâ‚‚ at all times.
  • Use 50% N2O / 50% O2 PRN with practical continuous duration limits (often <=6 h).

Adult - Inhalational

  • Self-administered via mask or mouthpiece demand valve.

Route constraints

  • No IV route; inhalational delivery only.

Pediatric

  • Same concentration if cooperative and supervised.

Renal adjustment

  • No adjustment needed.

Hepatic adjustment

  • No adjustment needed.

Warnings

Clinical warnings

  • Pneumothorax/trapped gas expansion risk.
  • Pulmonary hypertension → risk of increased pulmonary vascular resistance (PVR) and right ventricular (RV) failure.
  • Inactivates vitamin B12 (methionine synthase inhibition) → neurologic toxicity risk with prolonged/repeated exposure (myelopathy, neuropathy).
  • B12 deficiency risk can occur even with short exposure in susceptible patients (inactivation of methionine synthase).
  • B12 inactivation → hyperhomocysteinemia → thrombosis risk in susceptible patients.
  • Diffusion hypoxia risk immediately after discontinuation — administer 100% oxygen for at least 5 minutes post-use.
  • Increased risk of postoperative nausea and vomiting (PONV).
  • Recreational misuse can cause severe neurotoxicity.
  • Occupational exposure risk → chronic neurologic and reproductive toxicity.

Adverse effects

  • Common: dizziness, nausea, dysphoria.
  • Serious: hypoxia, neurologic toxicity with repeated/chronic exposure.

Contraindications / caution

Do not use

  • Pneumothorax — ABSOLUTE contraindication.
  • Air embolism, pulmonary blebs.
  • Recent scuba diving / decompression risk.
  • Any trapped gas condition (middle ear, intracranial air, bowel obstruction).
  • Intraocular gas (recent retinal surgery; e.g., SF6, C3F8) — ABSOLUTE contraindication.
  • Severe B12 deficiency.

Use caution / avoid high doses

  • Pulmonary hypertension → avoid if moderate–severe (risk of RV failure).
  • Increased intracranial pressure → avoid in TBI/neurosurgical patients.
  • Middle ear surgery → risk of pressure expansion and surgical failure.
  • Elderly (B12 deficiency risk).
  • Pregnancy first-trimester elective exposure.
  • COPD with high oxygen requirement.

Drug interactions

  • Opioids -> increased respiratory depression (especially avoid combination in labor settings).
  • Benzodiazepines -> additive sedation.
  • Alcohol -> additive CNS and respiratory depression.
  • B12 deficiency states -> worsened neurologic toxicity risk.
  • Methotrexate → risk of severe bone marrow suppression.

Special populations

Pediatrics

Useful when cooperative with mask/mouthpiece delivery.

Pregnancy

Generally safe for labor analgesia.

Breastfeeding

Safe after recovery due to rapid elimination.

Elderly

Screen for B12 deficiency risk.

Liver disease

Generally safe without adjustment.

Renal impairment

Generally safe without adjustment.

Administration

  • Always deliver with ≥30% oxygen minimum — must not use hypoxic mixtures.
  • Use oxygen analyzer and fail-safe delivery system.
  • Self-administered via mask or mouthpiece.
  • Demand-valve system preferred.
  • Patient-controlled mask (self-administration) is a safety feature → helps prevent overdose.
  • Start inhalation 2–3 minutes before painful stimulus for peak effect.
  • After discontinuation, administer 100% oxygen for at least 5 minutes to reduce diffusion hypoxia risk.

Monitoring

  • Continuous verification of oxygen delivery (avoid hypoxic mixtures).
  • RR, SpO2, and level of consciousness (minimum monitoring required).
  • Blood pressure if prolonged use.
  • Nausea/dizziness symptoms.
  • Monitor for diffusion hypoxia immediately after discontinuation.
  • In chronic/repeated exposure, monitor B12 and FBC.

Overdose / toxicity

Remove exposure -> 100% oxygen immediately -> airway/ventilation support -> monitor for diffusion hypoxia.

Recognition

  • Primary toxicity mechanism is hypoxic gas delivery (delivery system error).
  • Hypoxia, confusion, and reduced consciousness can occur acutely.
  • Chronic toxicity may present with neuropathy, ataxia, and anemia.

Immediate actions

  • High-flow oxygen.
  • Airway support as needed.
  • Supportive hemodynamic/respiratory care.

Antidote

  • No specific antidote.

Decontamination

  • Not applicable.

Escalation

  • ICU if severe hypoxia or neurologic instability.

Clinical pearls

Common mistakes, resistance logic, and bedside traps

Gas safety first

  • Always exclude trapped gas pathology before use.

Practical niche

  • Excellent fit for ER fractures and labor analgesia pathways.

Anesthetic ceiling

  • Not a full anesthetic alone - provides analgesia with weak anesthetic effect.
  • Not a full anesthetic alone -> provides analgesia with weak anesthetic potency (requires adjuncts for procedures).
  • Avoid in ANY closed gas space (e.g., bowel obstruction, pneumothorax, middle ear disease, intracranial air).

Self-administration

  • Patient self-administration is an important built-in safety mechanism.

Post-use oxygen

  • Always give oxygen after stopping to reduce diffusion hypoxia.

B12 vigilance

  • Think B12 deficiency in chronic users or unexplained neurologic symptoms.

Pharmacokinetics

  • Rapid pulmonary uptake.
  • Minimal metabolism.
  • Eliminated primarily by exhalation.
  • Expands closed/trapped gas spaces.

Mechanism of action

  • NMDA receptor antagonism.
  • Also activates opioid and noradrenergic pathways.
  • Produces analgesia more than true anesthesia at Entonox concentrations.

Common brand names

Saudi Arabia

Entonox · Medical Nitrous Oxide (Gulf Cryo, AHG)

Global

Nitronox · Generic N2O/O2 premix

Common trade names are curated examples only — formulations and availability vary. Verify the exact product name with your local pharmacy and national regulator before prescribing or dispensing.

Country practice notes

  • Widely used in GCC ER, EMS, and labor wards as Entonox.
  • Common supply channels include Gulf Cryo and AHG across Saudi/Gulf hospitals.
  • First-line prehospital trauma analgesia in many systems.
  • Available in most MOH and private hospital settings.

Saudi Arabia — confirm with local formulary.